LIST OF ABBREVIATIONS

Abbreviation		Stands for
µg	**:**	Microgram
ng	**:**	Nanogram
ACL	**:**	Anterior cruciate ligament
ADAMTS	**:**	A disintegrin-like and metalloproteinases with thrombospondin motifs
AP1	**:**	Activator protein 1
ATF	**:**	Activating transcription factor
Bil	**:**	Bilateral
BMI	**:**	Body mass index
CCR4	**:**	Chemokine (C-C motif) receptor 4
COX	**:**	Cyclo-oxygenase
CRP	**:**	C-reactive protein
DMOAD	**:**	Disease-modifying osteoarthritis drug
ECM	**:**	Extracellular matrix
ELISA	**:**	Enzyme-linked immunosorbent asasy
EMA		European Medicines Agency
ERK1/2	**:**	Extracellular signal-regulated kinases
ESR	**:**	Erythrocyte sedimentation rate
FAP ∞	**:**	Fibroblast activation protein ∞
G1cAT-1	**:**	Galactose-β-1, 3-glucuronosyltransferase I
HA	**:**	Hyaluronic acid
ICE	**:**	Interleukin-1 beta-converting enzyme
IL-1	**:**	Interleukin-1
IL-1 β	**:**	Interleukin-1 beta
IL-18	**:**	Interleukin-18
IL-1Ra	**:**	Interleukin-1 receptor antagonist
IL-1RII	**:**	Type II interleukin-1 decoy receptor
IL-IRI	**:**	Type I interleukin-1 decoy receptor
i NOS	**:**	Inducible nitric oxide synthetase
JNK	**:**	Jun N-terminal kinase
KL	**:**	Kellgren-Lawrence grade

obeikandl.com

Lt	**:**	Left
MMP	**:**	Matrix metalloproteinases
MR	**:**	Modified Release
MRI	**:**	Magnetic resonance imaging
mRNA	**:**	Messenger ribonucleic acid
NF-kB	**:**	Nuclear factor kappa B
NO	**:**	Nitric oxide
NSAID	**:**	Nonsteroidal anti-inflammatory drug
OA	**:**	Osteoarthritis
OD	**:**	Optical density
ONOO-	**:**	Peroxynitrite
PG	**:**	Proteoglycan
PKC	**:**	Protein kinase C
QFM	**:**	Quadriceps femoris muscle
RA	**:**	Rheumatoid arthritis
RANTES	**:**	Regulated upon activation normal T cell expressed and presumably secreted
ROM	**:**	Range of motion
Rt	**:**	Right
TGF	**:**	Transforming growth factor
TNF-α	**:**	Tumour necrosis factor-alpha
u PAR	**:**	Urokinase-type plasminogen activator receptor
VAS	**:**	Visual analogue scale
VRS	**:**	Verbal rating scale

opekandl.com

LIST OF TABLES

Tables No.		Page
(1)	Materials supplied for measurement of IL1β	**21**
(2)	Distribution of cases enrolled in each of the study groups.	**25**
(3)	Demographic data of the studied patients.	**26**
(4)	Clinical characteristics of knee osteoarthritis in the 3 studied groups.	**28**
(5)	Quadriceps muscle power in the 3 studied groups during initial and the two follow up assessment.	**29**
(6)	Hamstring muscle power in the 3 studied groups during initial and the two follow up assessment.	**30**
(7a)	Range of motion (ROM) of affected knees of the patients in the 3 studied groups during initial and the two follow up assessment.	**31**
(7b)	Range of motion of affected knees of the patients in the 3 studied groups during initial and the two follow up assessment.	**32**
(8)	Pain visual analogue, pain verbal rating scales and 20 meters fast walking time in the 3 studied groups during initial and 2 follow up assessment.	**34**
(9)	Comparison between the 3 studied groups regarding pain VAS, pain VRS and 20 meters fast walking time.	**41**
(10)	Comparison between the 3 studied groups regarding quadriceps muscle power at before treatment and 1 and 2 months follow up assessment.	**48**
(11)	Comparison between the 3 studied groups regarding hamstring muscle power at before treatment and 1 and 2 months follow up assessment.	**49**
(12)	Synovial and serum IL-1β level of the studied groups at initial and follow up assessment.	**53**
(13)	Synovial and serum IL-1β level in the patients and control group before treatment and 2 months after treatment.	**58**
(14)	Frequency of side effects of diclofenac sodium and diacerein	**62**

obeikandi.com

LIST OF FIGURES

Figures No.		Page
(1)	Standard curve of IL-1β	**22**
(2)	Box plot for median VAS and its range in Group I between before, 1 and 2 months after treatment.	**35**
(3)	Box plot for median VAS and its range in Group II between before, 1 and 2 months after treatment	**35**
(4)	Box plot for median VAS and its range in Group III between before, 1 and 2 months after treatment.	**36**
(5)	Box plot for median VRS and its range in Group I between before, 1 and 2 months after treatment.	**36**
(6)	Box plot for median VRS and its range in Group II between before, 1 and 2 months after treatment.	**37**
(7)	Box plot for median VRS and its range in Group III between before, 1 and 2 months after treatment.	**37**
(8)	Box plot for median 20 meters fast walking time and its range in Group I between before, 1 and 2 months after treatment.	**38**
(9)	Box plot for median 20 meters fast walking time and its range in Group II between before, 1 and 2 months after treatment.	**38**
(10)	Box plot for median 20 meters fast walking time and its range in Group III between before, 1 and 2 months after treatment.	**39**
(11)	Box plot for median difference of VAS between before and 1 month after treatment and its range in 3 different groups of treatment.	**42**
(12)	Box plot for median difference of VAS between 1 month and 2 months after treatment and its range in 3 different groups of treatment.	**42**
(13)	Box plot for median difference of VAS between before and 2 months after treatment and its range in 3 different groups of treatment.	**43**
(14)	Box plot for median difference of VRS between before and 1 month after treatment and its range in 3 different groups of treatment.	**43**
(15)	Box plot for median difference of VRS between 1 month and 2 months after treatment and its range in 3 different groups of treatment.	**44**
(16)	Box plot for median difference of VRS between before and 2 months after treatment and its range in 3 different groups of treatment.	**44**
(17)	Box plot for median difference of 20 meters fast walking time between before and 1 month after treatment and its range in 3 different groups of treatment.	**45**

openkemal.com

Figures No.		Page
(18)	Box plot for median difference of 20 meters fast walking time between 1 month and 2 months after treatment and its range in 3 different groups of treatment.	**45**
(19)	Box plot for median difference of 20 meters fast walking time between before and 2 months after treatment and its range in 3 different groups of treatment.	**46**
(20)	Lateral radiograph of the knee joint showing the patellofemoral articulation	**50**
(21)	Radiograph showing the anteroposterior view of the knee joint	**51**
(22)	Box plot for median synovial IL-1β and its range in group I between before, 1 and 2 month after treatment.	**54**
(23)	Box plot for median synovial IL-1β and its range in group III between before, 1 and 2 month after treatment.	**54**
(24)	Box plot for median blood IL-1β and its range in group I between before, 1 and 2 month after treatment.	**55**
(25)	Box plot for median blood IL-1β and its range in group II between before, 1 and 2 month after treatment.	**55**
(26)	Box plot for median blood IL-1β and its range in group III between before, 1 and 2 month after treatment.	**56**
(27)	Box plot for median synovial IL-1β before treatment and its range between the 3 groups of treatment and controls.	**59**
(28)	Box plot for median synovial IL-1β 2 months after treatment and its range between the 3 groups of treatment and controls.	**59**
(29)	Box plot for median blood IL-1β before treatment and its range between the 3 groups of treatment and controls.	**60**
(30)	Box plot for median blood IL-1β 2 months after treatment and its range between the 3 groups of treatment and controls.	**60**

obeikandl.com